Target intelligence / Profile preview

F1 capsular antigen protein of Yersinia pestis (F1 antigen)

Target
F1 antigen
Molecular classification
Other (capsular protein antigen), Virulence factor, Chaperone/usher pathway-assembled polymeric protein
01

Overview

F1 capsular antigen protein of Yersinia pestis (F1 antigen) is a capsule-like protein polymer (main subunit Caf1, 15.5 kDa), produced at mammalian host temperatures (37°C), and encoded by the caf1 gene on the unique pFra plasmid. Its assembly relies on the chaperone/usher pathway (Caf1M chaperone, Caf1A usher, and Caf1R regulator). It forms noncovalently associated fibrils on the bacterial surface, providing antiphagocytic properties by shielding Y. pestis from receptor interaction and macrophage-mediated clearance. The F1 antigen is not essential for virulence but enhances plague lethality, high bacteremia, and efficiency of flea-borne transmission. It is the major molecular target for anti-plague vaccine development, elicits rapid T-cell-independent humoral immunity, and is a recognized immunogen for diagnostics and vaccine design. There are no approved therapeutic drugs directly targeting F1, though monoclonal antibody and subunit vaccine strategies remain in active development.

Other names
Fraction 1 antigenF1 capsuleCaf1 (structural subunit)F1 capsular protein
02

Mechanism of action

Vaccines: Elicit protective humoral immunity—rapid anti-F1 IgG and IgM antibody responses. Monoclonal antibodies: Passive transfer provides protection by opsonizing bacteria and promoting their phagocytosis.

03

Biological functions

Immune evasion (inhibits phagocytosis by host macrophages)Facilitates transmission (promotes bacteremia required for flea-borne transmission)Induces protective immune responses (serves as a key immunogen for adaptive immunity in hosts)Capsule formation (forms a capsule-like envelope around bacteria)
04

Disease associations

Infection (central antigenic and virulence determinant in plague)Other (enhancer of mammal-to-flea transmission cycle for plague)
05

Safety considerations

Immune evasion: F1 capsule limits innate immune clearance, supporting severe bacteremia until the terminal stages of plagueVaccine challenge: High molecular weight polymeric F1 is required for robust humoral immunity
06

Interacting drugs

Vaccines incorporating F1 antigen, sometimes fused with LcrV antigen, under development and clinical evaluation

1 more in the full profile.

07

Biomarkers

Anti-F1 IgG/IgM titers: Used as markers for protective immunity following vaccination or infection

Beyond the preview

Go deeper on F1 capsular antigen protein of Yersinia pestis (F1 antigen).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on F1 capsular antigen protein of Yersinia pestis (F1 antigen).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call